Global EditionASIA 中文雙語Fran?ais
    Business
    Home / Business / The Third China International Import Expo

    Global pharma firms take CIIE pill for growth

    By ZHOU WENTING in Shanghai | China Daily | Updated: 2020-11-10 09:22
    Share
    Share - WeChat
    A visitor looks at medicines on display at the third China International Import Expo in Shanghai. WANG ZHUANGFEI/CHINA DAILY

    Cooperation to help foster a more innovative healthcare ecosystem

    International pharmaceutical companies signed several agreements on extended research and development cooperation and new drug development with their Chinese partners at the ongoing third China International Import Expo to better contribute to a more innovative healthcare ecosystem in China.

    Novo Nordisk, the Denmarkbased biopharmaceutical company, inked an agreement on Saturday to set up a new entity for research and development, marketing, import and distribution of finished medicines. The new entity, Novo Nordisk (Shanghai) Pharma Trading Co Ltd, will be set up in the Lingang New Area, a section of the China (Shanghai) Pilot Free Trade Zone, and have a total investment of 200 million yuan ($30 million).

    "China's continuously improving business environment, growing innovation ecosystem, and its stable policy environment gives us confidence in the future of the market," said Christine Zhou, senior vice-president and president for the China region for Novo Nordisk.

    According to Zhou, the country's dual circulation development pattern has inspired Novo Nordisk to further grow its research and development activities from China and for China.

    "With the help of the measures to deepen China's reform and opening-up such as the hosting of the CIIE, the company will work to grow its business and make changes in the diabetes and other chronic disease situations in the country," Zhou said.

    Swiss pharmaceutical company Roche was one of the first MNCs to have a strong research focus in China. Set up in 2004, the company's R&D center was the first to be established by a multinational pharmaceutical company in Shanghai.

    In October 2019, Roche upgraded the center into the Roche Innovation Center Shanghai, making it the company's third global R&D center following the one at its headquarters in Basel, Switzerland, and the other in San Francisco, the United States. The new center is focused on the research and early development of innovative drugs for treating immunity, inflammation and anti-infectious diseases. It currently has about 150 scientists, with over 90 percent of them coming from China.

    By the end of August, 257 invention patent applications had been submitted based on inventions and creations from the center, and 144 had been granted in China, the US, the European Union, and Japan. In addition, nine molecules, the development of which involved the innovation center, have entered clinical trial phases.

    US-based Pfizer, which established the Pfizer (China) Research and Development Center in Shanghai in 2005, said the center is a key pivot in the company's global R&D network and the company will continue to prioritize China with increasingly core technologies and resources.

    Jessie Chen, general manager of the Pfizer (China) Research and Development Center, said the company hopes to step up collaborations with the industry. "We want to create a world-class biopharmaceutical R&D ecological environment in China, which is part of the shared global R&D community, and help the country's local clinical research go international," she said.

    The company's goal is for China to be involved in at least 80 percent of its global early-phase and key clinical research programs within three years and 80 percent of its programs to be submitted for approval in the country simultaneously and to be introduced to the market.

    Moreover, the company plans to gradually involve the country in more phase I and II clinical trials to assist Chinese medical workers to accumulate experience in this area. It will also make innovative drugs available to Chinese patients more quickly, the company said.

    The global phase III clinical trials of an innovative targeted drug to treat lung cancer, which was approved in the country last year, was led by a professor in Guangdong province and another in Hong Kong. The therapy was also approved in many other countries and regions with its clinical trial results.

    Boston Scientific established its first overseas R&D center in Shanghai a decade ago. A team of more than 70 local engineers has leveraged insights into the local market to roll out products that meet local patients' needs and international requirements.

    A star exhibit from the company at the CIIE, which avails of digital technologies to provide remote clinical support for physicians, was developed by the China R&D team.

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    CLOSE
     
    亚洲AV中文无码乱人伦| 精品久久久久中文字| 无码人妻丰满熟妇啪啪网站| 国产福利电影一区二区三区久久老子无码午夜伦不 | 久久亚洲国产成人精品无码区| 久久无码国产专区精品| 精品久久无码中文字幕| 精品久久久无码人妻中文字幕| 日韩精品无码熟人妻视频| 无码国产精品一区二区免费式影视 | 最近的中文字幕在线看视频| 国精品无码一区二区三区左线| 中文字幕精品亚洲无线码一区应用| 久久亚洲中文字幕精品一区| 久久久久亚洲?V成人无码| 欧洲Av无码放荡人妇网站| 一本一道av中文字幕无码| 中文字幕亚洲综合久久菠萝蜜| 欧美激情中文字幕| 久久人妻AV中文字幕| 永久免费无码日韩视频| 中文无码一区二区不卡αv| 国产日韩精品无码区免费专区国产| 免费人妻无码不卡中文字幕系| 无码午夜成人1000部免费视频 | 再看日本中文字幕在线观看| 天堂√在线中文最新版| 在线免费中文字幕| 台湾佬中文娱乐中文| 国产中文字幕乱人伦在线观看 | 无码夫の前で人妻を侵犯| 最好看最新的中文字幕免费| 中文在线√天堂| 国产高清中文手机在线观看| 中文字幕在线免费看线人| 日韩精品一区二区三区中文字幕 | 国内精品无码一区二区三区 | 无码无套少妇毛多18PXXXX| 无码成A毛片免费| 精品久久久久久无码人妻热| 天堂亚洲国产中文在线|